Shareholder structure
Shareholder structure & information on capital, voting securities and voting rights
History of capital
Ablynx NV publishes the following information in accordance with Article 15 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"):
Total amount of the capital of the Company : |
EUR 81,486,264.59 |
Total number of voting securities: |
43,601,797 |
Total number of voting rights (denominator): |
43,601,797 |
Ablynx NV has an aggregate of 3,568,076 outstanding warrants, 2,506,512 warrants of which entitle their holders to an aggregate of 1,253,256 shares (two warrants giving right to subscribe for one share) and 1,061,564 warrants of which entitle their holders to an aggregate of 1,061,564 shares (one warrant giving right to subscribe for one share). The aggregate number of voting rights that can be obtained upon exercise of the outstanding warrants amounts to 2,314,820.
Ablynx NV has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares without voting rights.
The voting securities of Ablynx NV are not divided into categories.
The Articles of Association of Ablynx NV provide for an additional notification threshold of 3%.
This information is valid as of 21 April 2010. In accordance with the Transparency Law, changes to the information set out above will be published ultimately by the end of the calendar month during which the relevant change has occurred.
Shareholder structure
In accordance with Article 14 of the Belgian Transparency Law, Ablynx hereby publishes its shareholder structure.
Holdings as per 1 September 2008
Ablynx received the following notifications of holdings as per 1 September 2008. The denominator as per 1 September 2008 amounted to 36,438,959.
Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV
|
6,924,764 |
19.00% |
Abingworth Management Limited and Abingworth LLP |
4,102,952 |
11.26% |
Gilde Europe Food & Agribusiness Fund B.V. |
2,941,772 |
8.07% |
Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia |
1,900,000 |
5.21% |
VIB VZW |
1,375,000 |
3.77% |
Holdings as per 18 March 2010
Ablynx received the following notifications of holdings as per 18 March 2010. The denominator as per 18 March 2010 amounted to 43,590,173.
Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV |
7,991,431 |
18,33% |
Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia |
1,900,000 |
4,36% |
Holdings as per 21 April 2010
Ablynx received the following notification of holding as per 21 April 2010. The current denominator as per 21 April 2010 amounted (and still amounts) to 43,601,797.
KBC Groep NV and KBC Private Equity NV |
1,411,556 |
3,24% |
Shareholder structure as per 21 April 2010 – for information purposes only
Based on (i) the number of voting rights set out in the notifications received by Ablynx as per 1 September 2008 (following the entry into force of the Belgian Transparency Law), and (ii) the new number of voting rights set out in the notifications received by Ablynx as per 18 March 2010, and taking into consideration the current denominator (43,601,797), Ablynx hereby states, for information purposes only, that the shareholder structure would be the following:
NOTIFYING PERSON(S)
|
Number of voting rights notified on1/09/2008 |
Number of voting rights notified on 18/03/2010 and21/04/2010 respectively
|
Hypothetical percentage of voting rights based on current denominator and most recent notifications |
Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV |
6,924,764 |
7,991,431 |
18.33% |
Sofinnova Partners SAS |
5,927,830 |
- |
13.60% |
Abingworth Management Limited and Abingworth LLP |
4,102,952 |
- |
9.41% |
Alta California Partners IV, LP |
3,135,583 |
- |
7.19% |
Gilde Europe Food & Agribusiness Fund B.V. |
2,941,772 |
- |
6.75% |
C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim International GmbH |
2,142,857 |
2,142,857 |
4.92% |
Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia |
1,900,000 |
1,900,000 |
4.36% |
VIB VZW |
1,375,000 |
- |
3.15% |
KBC Groep NV and KBC Private Equity NV |
1,589,286 |
1,411,556 |
3.24% |
Transparency notifications
Article 15 of the Articles of Association of the Company has set the threshold requiring a transparency declaration at 3%, 5% and each subsequent multiple of 5%.
|
 |
Latest News
27/07/2010 ABLYNX ANNOUNCES CHANGE IN MANAGEMENT
23/07/2010 ABLYNX ANNOUNCES WARRANT EXERCISE
12/07/2010 NOVARTIS OBTAINS LICENSES TO DEVELOP AND COMMERCIALISE TWO NOVEL NANOBODIES®
Email alerts
If you would like to receive updates on the company news, please
click here
|